For your adult patients with
MDS- or β-thalassemia–associated anemia
With Reblozyl®▼ —the first and only erythroid maturation agent—you can reduce or even eliminate patients’ red blood cell (RBC) transfusion dependence.1-3
Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the treatment of adult patients:
- with transfusion-dependent anemia due to very low, low or intermediate-risk (IPSS-R) myelodysplastic syndrome (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible to erythropoietin-based therapy
- with transfusion-dependent anemia associated with β-thalassemia.
The request has to be submitted via eHealth.
The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25mg/kg every 21 days for beta-thalassemia.
Reblozyl®▼ treatment will stop being reimbursed if:
- there is no reduction of the transfusion burden after 9 weeks (3 cycles) at the maximum dose level, if the lack of response cannot be explained otherwise (bleeding, surgical intervention, other concomitant disease) or,
- anytime in case of unacceptable toxicities.4
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl®▼, please refer to the SmPC. View the EU SmPC in English, SmPC in French, SmPC in Dutch.